

Transport in Technicolor: Mapping ATP-Binding Cassette Transporters in Sea Urchin Embryos

TUFAN GÖKIRMAK, LAUREN E. SHIPP, JOSEPH P. CAMPANALE, SASCHA C.T. NICKLISCH, AND AMRO HAMDOUN*

Marine Biology Research Division, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California



SUMMARY

One quarter of eukaryotic genes encode membrane proteins. These include nearly 1,000 transporters that translocate nutrients, signaling molecules, and xenobiotics across membranes. While it is well appreciated that membrane transport is critical for development, the specific roles of many transporters have remained cryptic, in part because of their abundance and the diversity of their substrates. Multidrug resistance ATP-binding cassette (ABC) efflux transporters are one example of cryptic membrane proteins. Although most organisms utilize these ABC transporters during embryonic development, many of these transporters have broad substrate specificity, and their developmental functions remain incompletely understood. Here, we review advances in our understanding of ABC transporters in sea urchin embryos, and methods developed to spatially and temporally map these proteins. These studies reveal that multifunctional transporters are required for signaling, homeostasis, and protection of the embryo, and shed light on how they are integrated into ancestral developmental pathways recapitulated in disease.

“[Multidrug resistance transporters] can be thought of as being more like Swiss army knives than vegetable peelers, with functions dictated by the cellular context in which they are expressed.”

* Corresponding author:
Scripps Institution of Oceanography
University of California
San Diego 9500 Gilman Dr., 0202
La Jolla, CA 92093.
E-mail: hamdoun@ucsd.edu

Grant sponsor: NIH; Grant numbers:
HD058070, ES021985; Grant sponsor:
NSF; Grant number: OCE1314480;
Grant sponsor: UC Cancer Research
Coordinating Committee and UCSD
Academic Senate; Grant number:
RL030S; Grant sponsor: NSF GRFP;
Grant number: DGE-1144086;
Grant sponsor: NDSEG;
Grant sponsor: EPA STAR;
Grant number: FP-91711601

Published online in Wiley Online Library
(wileyonlinelibrary.com).
DOI 10.1002/mrd.22357

Mol. Reprod. Dev. 2014. © 2014 Wiley Periodicals, Inc.

Received 7 May 2014; Accepted 27 June 2014

INTRODUCTION

ATP-Binding Cassette Transporters In Development and Disease

Although plasma membrane proteins comprise one quarter of all genes (Almén et al., 2009; Babcock and Li, 2014), our understanding of their functions during

development remains limited. This is of interest because the category of plasma membrane proteins includes nearly 1,000 transporters that govern embryo-environment

Abbreviations: ABC, ATP-binding cassette; CAM, calcein-acetoxymethyl ester; CMFDA, chloromethyl fluorescein diacetate; MDR, multidrug resistance; MRP, multidrug-resistance associated protein; SLC, solute carrier.

interactions and intercellular communication within the embryo. Among them are “active” transporters that translocate diverse molecules across membranes using power liberated by the direct hydrolysis of ATP. In eukaryotes, the largest group of active transporters is the ATP-binding cassette (ABC) family (Borst and Elferink, 2002); in humans, these include 49 genes divided among seven subfamilies, designated ABC A-G (Dean et al., 2001).

Multidrug resistance (MDR) transporters are a subset of ABC transporters that efflux endogenous and exogenous hydrophobic small molecules (Sharom, 2008). These include three subfamilies, the ABCB proteins, including ABCB1/permeability-glycoprotein/MDR1 and ABCB4/MDR3; the ABCC/multidrug resistance-associated proteins (MRP), including ABCC1/MRP1, ABCC2/MRP2 and ABCC3/MRP3; and the ABCG proteins, including ABCG2. These transporters can have a dramatic impact on drug disposition (Giacomini et al., 2010) and are often up-regulated in metastatic cancer, leading to chemotherapeutic resistance (Gottesman et al., 2002). Accordingly, these B-, C-, and G- proteins, and several other members of these families, are often designated MDR transporters.

Although MDR transporters have primarily been studied in the context of drug disposition, it is becoming increasingly appreciated that they are also widely expressed in embryos and stem cells (Barbet et al., 2012; Shipp and Hamdoun, 2012; Erdei et al., 2014). By analogy to their drug disposition in adults, one critical function in embryonic cells is presumably protection from xenobiotics. MDR transporters often have large, polyspecific binding sites that accommodate many structurally diverse substrates (Gutmann et al., 2010), including both xenobiotics and signaling molecules. Examples of signaling molecule substrates are platelet-activating factor (Raggers et al., 2001), leukotrienes (Deeley and Cole, 2006), prostaglandins (Russel et al., 2008), and cyclic nucleotides (Cheepala et al., 2013). These signaling molecules have been implicated in many processes of development, but the mechanisms governing their translocation and accumulation are often poorly understood.

Transporter-mediated signaling is emerging as a causative agent in the progression of diseases where transporters are overexpressed (Fletcher et al., 2010). In neuroblastoma, for example, ABCC1 expression is negatively correlated with clinical outcome, even in patients who do not receive chemotherapy, presumably by altering the distribution and/or abundance of endogenous substrates that control cell motility (Fletcher et al., 2010). These observations might suggest that MDR transporters have ancestral functions during development that are related to cell motility and migration, and that these functions become reactivated in disease.

Developmental functions of transporters are further suggested by the observation that pathways common to development and disease, such as the epithelial-mesenchymal transition, can regulate MDR transporters. During embryonic development of triploblastic animals, epithelial cells become mesenchymal through morphological changes, including loss of tight junctions, apical-basal

polarity, and cell adhesion; such changes enable individual cells to dissociate from the epithelial layer in which they originate (Thiery et al., 2009). Similarly during metastasis, many types of cancer cells shed epithelial characters, detach from the primary tumor through the epithelial-mesenchymal transition, and become motile (Yang and Weinberg, 2008). These epithelial-mesenchymal transitions can also upregulate MDR-transporter phenotypes in metastatic cancer cells (Arumugam et al., 2009; Saxena et al., 2011). Collectively, such observations suggest that an understanding of the function and regulation of MDR transporters in development would inform our understanding of their behavior in cancer.

ABC Transporters and MDR Transporter Activity In Sea Urchins

MDR transporters are expressed in oocytes, embryos, and stem cells of a variety of model systems, and the list of related plasma membrane proteins found in embryos continues to expand, currently including ABCB4, ABCB5, ABCB11, ABCC2, ABCC3, ABCC4, ABCC5, and ABCC10. Homologs of ABC transporters and MDR-transporter-like efflux activities have been reported in many embryos, perhaps most extensively studied in sea urchins (Good and Kuspa, 2000; Hamdoun et al., 2004; Yabe et al., 2005; Ricardo and Lehmann, 2009; Long et al., 2011; Gökirmak et al., 2012; Fischer et al., 2013; Miranda et al., 2013). While both developmental and protective functions have been proposed for these transporters, relatively few studies have systematically mapped the MDR transporter repertoire of an embryo. Studies on these transporters during the early development of sea urchin embryos, first described nearly a decade ago (Hamdoun et al., 2004), have started to provide insight into the diversity of transporters involved.

Given that marine embryos are exposed to a variety of natural toxins and anthropogenic contaminants (Epel et al., 2008), one function of sea urchin MDR transporter activity appears to be protecting embryos from xenobiotics. This was suggested by the fact that inhibitors of MDR transporters sensitize embryos to environmental toxicants (Bosnjak et al., 2009) as well as chemotherapy drugs such as vinblastine (Hamdoun et al., 2004; De Souza et al., 2010; Anselmo et al., 2012) and etoposide (Epel et al., 2006). Pollutants such as mercuric chloride (Bosnjak et al., 2009) and antifouling agents (Bosnjak et al., 2011; Xu et al., 2011) were also shown to be substrates of MDR transporters. In addition to protecting embryos from chemical insults, transporters protect against ultraviolet radiation, albeit the mechanism remains unknown (Leite et al., 2014).

Additional insights into the functions of sea urchin MDR transporters come from genomics. The purple sea urchin (*Strongylocentrotus purpuratus*) genome currently has 82 reliable ABC transporter gene annotations (EchinoBase.org; Goldstone et al., 2006; Sodergren et al., 2006). At least 75 of the 82 genes are expressed in early larval stages, highlighting their importance by development. The expansion in sea urchin ABC genes, as compared to humans

(Vasiliou et al., 2009), is primarily in the MDR transporter families B, C, and G –including 13 ABCB genes, 31 ABCC genes, and 9 ABCG genes. At least 20 B, C, and G genes are expressed by gastrulation (Shipp and Hamdoun, 2012) and the corresponding proteins encoded by these 20 genes are predicted to function in diverse processes including cell signaling, lysosomal and mitochondrial homeostasis,

potassium channel regulation, pigmentation, and protection from xenobiotics (Shipp and Hamdoun, 2012).

Insights into the regulation and developmental significance of these proteins have come from studies revealing that B- and C-type efflux transport is dynamic in early development (Fig. 1A). For example, there is an 80-fold increase in MDR transporter activity that occurs 25 min




Figure 1. Transitions in MDR transporter activity during development. **A:** Schematic illustration of switches in MDR transporter activity during sea urchin development. Efflux activity increases 25 min after fertilization (cell color transitioning from dark to light green) and later decreases in small micromeres of 60-cell embryos (light to dark green), as demonstrated by changes in calcein accumulation. **B:** Confocal micrographs show differences in calcein accumulation (green) after the egg-to-embryo and soma-to-germ line (a.k.a. micromere-to-small micromere) transition. **C:** Confocal maximum intensity projections (MIP) and cross-sections showing calcein accumulation after treatment with 10 μ M PSC833 (MDR-transporter inhibitor) or 10 μ M MK-571 (MRP inhibitor) in 16-hour-old blastulae. All embryos were imaged and displayed with the same settings, but brightness of control embryos was increased in this figure to make them apparent. **D:** Schematic of a calcein-AM efflux assay in polarized epithelial cells of the blastula. (1) Calcein-AM passes into/through the plasma membrane where it is (2) recognized and effluxed by an ABC transporter or (3) cleaved into the fluorescent product, calcein, by intracellular esterases. Calcein is fluorescent and membrane impermeable, and can therefore accumulate in the cytoplasm.

after fertilization (Fig. 1B). This increase in activity does not require *de novo* gene expression, but is instead mediated by actin-dependent translocation of transporters stored in the unfertilized eggs to the tips of microvilli in zygotes, via a Rab11-dependent mechanism (Hamdoun et al., 2004; Whalen et al., 2012). Such regulation of transporter activity is analogous to that reported in mammalian adult hepatocytes, where bile acid secretion is regulated by serine/threonine kinases (LKB1 and AMPK1) (Fu et al., 2011; Homolya et al., 2014) and trafficking of ABCB11 from Rab11 and myosin Vb-positive vesicles to the apical surface (Wakabayashi et al., 2006).

Of interest is whether the LKB1-AMPK1 pathway, or other kinase signaling pathways, might also control transporter activity in embryos. LKB1-AMPK1 signaling is involved in developmental programs and in various disease phenotypes. For instance, in *Lkb1*-knockout mouse embryos, neural tube closure, somitogenesis, and vascular development are defective (Ylikorkala et al., 2001; Londesborough et al., 2008). In disease, LKB1 is a tumor repressor and LKB1 knockdown causes epithelial-mesenchymal transition in lung carcinogenesis (Roy et al., 2010), suggesting that the LKB1-AMPK1 signaling pathway may be involved in epithelial-mesenchymal-transition-induced multidrug resistance.

In sea urchin embryos, MDR transporter activity remains high in early development, but is down-regulated only in small micromeres, the presumptive germ-line progenitors (Fig. 1B and C). This is unexpected given that high transport activity is seen in some stem cells, although a likely possibility is that modulation of transporter activity is necessary for primordial-germ-cell functions such as migration (Campanale and Hamdoun, 2012; Campanale et al., 2014). Another developmentally regulated ABC transporter is ABCC5a, which is expressed only transiently during development (Shipp and Hamdoun, 2012). Though the precise developmental function of ABCC5 remains unknown, a recent report suggested that ABCC5 has a conserved role in heme homeostasis and hematopoiesis (Korolnek et al., 2014). Interestingly, sea urchin ABCC5a is spatially restricted to newly forming secondary mesenchyme, the precursors of larval immunocytes (Shipp and Hamdoun, 2012; Solek et al., 2013).

Given the diversity of transporters utilized by embryos, the proposed roles for ABC transporters are clearly the “tip of the iceberg”. Here, we summarize approaches for mapping MDR transporters in sea urchin embryos, and the implications of these studies for understanding transporter function. We review methods for measuring efflux activities using fluorescent substrates, expression of recombinant proteins, and mapping of transporter localization. Although we focus on MDR transporters, which we define as plasma membrane proteins in the B, C, and G families, the techniques are also applicable to the study of other types of membrane proteins, such as solute carrier (SLC) transporters (Wu et al., 2011b) and amino acid transporters (Meyer and Manahan, 2009), and they provide a road map for the study of membrane transporters in other embryo models (Fischer et al., 2013).

FROM GENE TO FUNCTION: EFFLUX ASSAYS, EXPRESSION OF RECOMBINANT TRANSPORTERS, AND MAPPING TRANSPORT WITHIN THE EMBRYO

Use of Efflux Assays to Study MDR Transporter Function

Efflux assays with fluorescent substrates were first developed to assess MDR transporter function in drug-resistant cancer cells (Homolya et al., 1993; Homolya et al., 1996). Since then, they have been adapted for applications ranging from drug discovery (Polli et al., 2001; Tegos et al., 2014) to pollutant testing (Hamdoun et al., 2002; Smital et al., 2004; Bosnjak et al., 2009; Xu et al., 2011) to developmental studies (Hamdoun et al., 2004; Campanale and Hamdoun, 2012; Whalen et al., 2012). MDR transporter activity is assessed by measuring the accumulation of fluorescent transporter substrates (Table 1). If transporter activity is high, fluorescent substrates are effluxed and intracellular fluorescence is low; conversely, low transporter activity allows fluorescent substrates to accumulate, leading to high intracellular fluorescence (Figure 1).

Fluorescent efflux assays can be performed with different detection tools, such as a spectrofluorometer (Cole et al., 2013) or microscope (Campanale and Hamdoun, 2012; Gökirmak et al., 2012). Our group has favored the use of confocal microscopy since this method can be used for quantitative and/or qualitative measurement of transport. As compared to spectrophotometry of homogenates or widefield microscopy, confocal microscopy further enables the measurement of differences in efflux between cell types of the embryo (Campanale and Hamdoun, 2012).

Fluorescent Substrates of MDR Transporters

Due to their polyspecificity, MDR transporters can efflux a wide variety of structurally diverse compounds. Conveniently, these include many fluorescent small molecules (<1000 Da), which can be readily visualized in efflux assays (Litman et al., 2000; Lebedeva et al., 2011; Strouse et al., 2013). Interactions between mammalian MDR transporters and fluorescent substrates are well characterized, allowing the use of this approach to understand the efflux functions of embryo transporters. Functional characterization of sea urchin MDR transporters with these molecules, showed that they have similar efflux activities to their closest human homologs (Gökirmak et al., 2012).

Fluorescent substrates can be grouped into four major categories (Table 1). The first category contains the fluorone-based synthetic compounds, including rhodamines (e.g. rhodamine 123, rhodamine B, and rhodamine 6G); calcein-acetoxymethyl ester (CAM); 2', 7'-bis-(2-Carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM); Fluo3-AM; fluorescein diacetate (FDA); and chloromethyl fluorescein diacetate (CMFDA). Among them, CAM has been the probe most commonly used in echinoderm eggs and embryos (Hamdoun et al., 2004; Roepke et al., 2006; Campanale and Hamdoun, 2012; Gökirmak et al., 2012). CAM is a neutral, non-fluorescent, membrane-permeable substrate of ABCB- and ABCC-type

TABLE 1. Fluorescent Substrates of MDR Transporters

Dye Class	Fluorescent Dye	Target MDR Transporter			References
		ABCB1	ABCC1	ABCG2	
Fluorone	Rhodamine 123	+	–	+	Litman et al. (2000); Szakács et al. (2008)
	Calcein-AM/calcein	+	+	–	Litman et al. (2000); Gökirmak et al. (2012)
	BCECF-AM/BCECF	+ ^a	+ ^a	–	Draper et al. (1997); Homolya et al. (1993)
	Fluo3-AM	N/D	+	N/D	Keppler et al. (1999)
	CMFDA	+ ^a	+ ^a	N/D	Weiss et al. (2007)
	FDA	+ ^a	+ ^a	N/D	McAleer et al. (1999)
Bodipy	Vinblastine	+	+	–	Litman et al. (2000); Gökirmak et al. (2012)
	Verapamil	+	–	–	Litman et al. (2000); Gökirmak et al. (2012)
	Paclitaxel	+	–	–	Litman et al. (2000)
	Prazosin	+	–	+	Litman et al. (2000)
Cyanine	JC-1	+	+	+	Strouse et al. (2013)
	MitoTracker Green	+ ^a	+	–	Marques-Santos et al. (2003); Strouse et al. (2013)
	SYTO stains	+	+	–	Strouse et al. (2013)
Anthracene	Doxorubicin	+	+	+	Litman et al. (2000); Szakács et al. (2006)
	Daunorubicin	+	+	+	Litman et al. (2000); Szakács et al. (2006)
	Bisantrene	+	–	+	Zhang et al. (1994); Litman et al. (2000)
	Epirubicin	+	+	+	Szakács et al. (2006)
	Mitoxantrone	+/-	+	+	Litman et al. (2000); Gökirmak et al. (2012)

+ verified substrate; – absence of transporter-substrate interaction; +/- interactions differ among species; N/D, not determined.

^aUnpublished observation in sea urchin embryos.

transporters in mammals and sea urchins. CAM passively diffuses across the cell membrane, and is converted to membrane-impermeable green fluorescent calcein after the cleavage of the acetoxymethyl ester (-AM) moiety by intracellular esterases (Fig. 1D) (Essodaigui et al., 1998). Therefore, cells with high ABCB and ABCC MDR transporter activity accumulate less calcein and exhibit lower fluorescence compared to cells with less activity. While fluorone-based dyes are typically not effective substrates of ABCG transporters, a related class of xanthene-based dyes are alternative substrates for these proteins (Lebedeva et al., 2011).

The second major group of fluorescent compounds includes the bodipy conjugates of MDR transporter substrates, including vinblastine, verapamil, paclitaxel, and prazosin (Litman et al., 2000). These substrates have no inherent fluorescence, but bodipy is strongly fluorescent and does not require esterase activity for activation. Bodipy is relatively nonpolar and neutral, which limits, but does not eliminate, effects on the substrates to which it is conjugated – thus, an important consideration when using these substrates as tracers in that the bodipy moiety can slightly alter the characteristics of the substrate to which it is attached. For example, bodipy-verapamil is more effectively transported by ABCB1 than unconjugated verapamil, and is also a less effective inhibitor (Lelong et al., 1991). Regarding specificity, bodipy conjugates of vinblastine and verapamil are well-characterized substrates for mammalian ABCB transporters (Litman et al., 2000; Crivellato et al., 2002; Kimchi-Sarfaty et al., 2002), and both are effluxed by sea urchin permeability-glycoprotein-type transporters such as ABCB1a and ABCB4a (Gökirmak et al., 2012). These observations illustrate the conservation of substrates between species.

The third class of fluorescent substrates includes cyanine-based fluorescent compounds such as JC-1 (a mitochondrial membrane potential probe), MitoTracker Green FM (a mitochondrial stain), and the SYTO series of nucleic acid stains. JC-1 is effluxed by all three major MDR transporters, and has been used in combination with niclosamide to probe ABCG2 activity (Strouse et al., 2013). MitoTracker Green FM is a substrate of both human and sea urchin ABCB type transporters (Marques-Santos et al., 2003; unpublished observations).

Finally, the fourth class of fluorescent MDR-transporter substrates contains the anthracene-derived antitumor drugs. These include doxorubicin, daunorubicin, bisantrene, epirubicin, and mitoxantrone (Litman et al., 2000). As they are inherently fluorescent, these drugs can be used as tools for studying efflux functions of MDR transporters in intact cells, but their cytotoxicity and comparatively low fluorescence make them difficult to use at optimal concentrations. In some cases, they remain the best available option. For example, mitoxantrone is effluxed by human ABCG2, and it is also a weak substrate for human ABCB1 (Litman et al., 2000; Sharom, 2008). In sea urchins, mitoxantrone is also effluxed by ABCG2a, but we were unable to detect significant efflux of this substrate by ABCB1a or ABCB4a (Gökirmak et al., 2012).

When using fluorescent-efflux assays to characterize MDR transporters, one limitation is the inability to resolve activities of individual transporters, as many MDR transporters display overlapping substrate specificity. For example, in humans, CMFDA can be effluxed by ABCC1, ABCC2, ABCC3, and ABCC5 transporters (McAleer et al., 1999; Weiss et al., 2007). In addition, some of the dyes used as substrates of MDR transporters are also substrates of SLC transporters. For example, Fluo-3 is transported both

TABLE 2. Inhibitors of MDR Transporters

Inhibitor Class	Inhibitor	Target MDR Transporter		References
		Primary	Secondary	
First Generation	Verapamil	ABCB1	ABCC1/ABCG2	Tsuruo et al. (1981); Germann et al. (1997); Anselmo et al. (2012) ^a
	Cyclosporin A	ABCB1	ABCC1/ABCG2	Qadir et al. (2005); Matsson et al. (2009); Hamdoun et al. (2004) ^a
	Amiodarone	ABCB1	ABCG2	Ford and Hait (1990); Matsson et al. (2009)
	Quinidine	ABCB1	ABCC1	Robert and Jarry (2003); Hamilton et al. (2001); Matsson et al. (2009)
Second and third Generation	Nifedipine	ABCB1	ABCG2	Philip et al. (1992); Zhang et al. (2005)
	R-Verapamil	ABCB1/ABCC1		Perrotton et al. (2007)
	PSC 833	ABCB1	ABCC1	Twentyman (1992); Leier et al. (1994); Campanale and Hamdoun (2012) ^a
	Elacridar	ABCB1/ABCG2		Hyafil et al. (1993); de Bruin et al. (1999); Oostendorp et al. (2009)
Fourth Generation	Tariquidar	ABCB1	ABCG2	Martin et al. (1999); Robey et al. (2004); Kannan et al. (2011)
	LY465803	ABCC1	ABCB1	Dantzig et al. (2004); Norman et al. (2005)
	LY475776	ABCC1	ABCB1	Dantzig et al. (2004)
	Fumitremorgin C	ABCG2		Rabindran et al. (2000); Matsson et al. (2007); Matsson et al. (2009)
Others	Ko143	ABCG2	ABCB1	Allen et al. (2002); Matsson et al. (2009)
	Curcumin	ABCB1/ABCC1/ABCG2		Wu et al. (2011a); Limtrakul et al. (2007)
	MK-571	ABCC1	ABCB1/ABCG2	Leier et al. (1994); Matsson et al. (2009); Fischer et al. (2013) ^a
	BAY u9773	ABCC1		Maeno et al. (2009)

^aReferences that show validation in embryos.

by inwardly directed SLC and outwardly directed ABC transporters (Sai and Tsuji, 2004; Baldes et al., 2006). One solution to this problem can be found by combining the use of fluorescent dyes with specific inhibitors. Indeed, a recent screen of 121 fluorescent compounds in multidrug-resistant human cell lines identified 31 substrates, which can be used in combination with inhibitors to specifically probe ABCB1, ABCC1, and ABCG2 transporter activities (Strouse et al., 2013).

Inhibitors of MDR Transporters

The efflux activity measured in embryos can occur from the action of multiple, redundant transporters. In sea urchins, for example, CAM is a substrate of ABCB1a, ABCB4a, and ABCC1 β , a splice variant of ABCC1 (Gökirmak et al., 2012; unpublished observations). Identifying the proportional contributions of individual transporters to the global efflux thus requires specific ABC transporter inhibitors. MDR-transporter inhibitors are often small molecules that were initially generated to improve drug retention in tumor cells. Attempts to discover such molecules have resulted in the development of preclinical and clinical drugs, some of which are useful for characterizing the efflux functions and structures of MDR transporters in vivo and in vitro. Most inhibitors target the major MDR transporters –such as ABCB1, ABCC1, ABCC2, and ABCG2– although, it is important to note that many of these compounds also inhibit other ABC transporters at higher concentrations (Table 2).

There have been four “generations” of MDR transporter inhibitors, each with successively greater levels of specificity for MDR transporters. First-generation inhibitors were derived from compounds with known biological functions, such as channel blockers (e.g. verapamil and nifedipine), immunosuppressants (e.g. cyclosporine), and cardiovascular drugs (e.g. amiodarone and quinidine). Since MDR transporters are often not the only targets of these compounds, they yielded limited clinical success due to their undesirable toxicity. For instance, verapamil, an L-type calcium channel blocker, sensitizes multidrug-resistant leukemia cells (Tsuruo et al., 1981) and later was shown to be a competitive inhibitor of ABCB1 (Yusa and Tsuruo, 1989); however, verapamil is cardiotoxic at the concentration that inhibits ABCB1 (Krishna and Mayer, 2000). In echinoderm embryos, verapamil and cyclosporine A were used to characterize ABCB activity (Hamdoun et al., 2004; De Souza et al., 2010; Anselmo et al., 2012). As with mammalian systems, the inhibition of sea urchin MDR transporters requires low micromolar concentrations of both compounds, whereas relatively high concentrations of verapamil are required to inhibit calcium channels (Kazazoglou et al., 1985).

Second- and third-generation MDR-transporter inhibitors were designed to address some of these targeting problems. Compounds of these generations include PSC833 (a non-immunosuppressant cyclosporine D analog), the R-enantiomer of verapamil (a lower affinity calcium channel antagonist), and anthranilic acid derivatives such as tariquidar and elacridar, which are potent inhibitors of

ABCB1 and ABCG2 transporters (Hyafil et al., 1993; de Bruin et al., 1999; Martin et al., 1999; Robey et al., 2004). Recently, a fluorophore conjugate of a tetrazole-containing analog of tariquidar, HM30181, was developed for real-time imaging of MDR transporter-inhibitor interactions (Sprachman et al., 2014). Among second- and third-generation inhibitors, PSC833 has been used in sea urchin embryos to study ABCB-type transporters (Fig. 1C; Table 2), although one of its limitations is poor solubility at high concentrations ($>10 \mu\text{M}$).

Fourth-generation MDR-transporter inhibitors include compounds discovered through screens from natural products extracted from plants, fungi, and marine organisms. This family of inhibitors consists of structurally diverse compounds that can be used as scaffolds for de novo synthesis and the design of new inhibitors (Wu et al., 2011a). For example, fumitromorgin C (FTC) is a highly specific ABCG2 inhibitor isolated from fungi (Rabindran et al., 2000), but its undesirable neurotoxicity leaves it unusable in medicine. Ko143, a structural analog of FTC, on the other hand, is not neurotoxic and is highly specific to ABCG2 (Allen et al., 2002).

Finally, although most of the initial efforts to reverse MDR transporter phenotypes focused on ABCB1, several compounds were found to specifically inhibit ABCC1 and ABCC2 (Table 2). Among those, MK-571, a leukotriene (LT) D4 analog, is commonly used (Cole, 2014). Although it was originally developed to inhibit cysteinyl leukotriene receptor 1 (CysLTR1) (Young, 1991), later reports show that it competitively inhibits ABCC1-mediated efflux of LTC₄ (Leier et al., 1994) and proved to be non-selective among MRP homologs, including ABCC2, ABCC3, ABCC4, and ABCC5 (Haimeur et al., 2004). Furthermore MK-571 can inhibit organic anion transporters at high concentrations (Keppler, 2011).

Other CysLTR1 antagonists, including ONO-1078, LY171883, and the dual CysLTR1/2 antagonist BAY u9773, were shown to competitively inhibit ABCC1 transporter activity, but the cross-inhibition of MRP homologs by these compounds still remains an issue (Cole, 2014). To overcome specificity issues, cyclohexyl-linked tricyclic isoxazole inhibitors were developed for ABCC1 transporters. LY465803 and its photoactive analog LY475776 are very potent competitive inhibitors of ABCC1 ($\text{IC}_{50} \sim 50 \text{ nM}$), and unlike MK-571, they do not inhibit the closely related transporter ABCC2 or other MRP homologs (Dantzig et al., 2004; Norman et al., 2005). Among these MRP inhibitors, only MK-571 (Fig. 1C) has been used in sea urchin embryos to date (Hamdoun et al., 2004; Epel et al., 2006; Bosnjak et al., 2009). Within sea urchins, it has proven to be an effective inhibitor of CAM efflux, although this could be due to its action on multiple transporters; therefore, it will be important to determine if alternative ABCC inhibitors are also effective and specific in sea urchins.

Linking Transporters to Substrates through the Expression of Recombinant Proteins

Efflux assays often fall short of linking a specific transporter to an observed activity due to the overlap in

substrates among transporters. In sea urchins, a simple method to address this is the expression of a recombinant transporter encoded by an exogenous mRNA that is injected into the one-cell embryo. Exogenous mRNA expression is a routine procedure used to study gene function in sea urchins (Cheers and Ettensohn, 2004), frogs (Churamani et al., 2012), zebrafish (Postel et al., 2011), amphioxus (Holland and Yu, 2004), starlet sea anemones (Layden et al., 2013), and fruit flies (Beumer et al., 2008). We recently adapted such methods for fluorescent protein tagging and expression of ABC transporters in sea urchins (Gökirmak et al., 2012).

Given the sensitivity of transporters to the location of fluorescent protein tags, we generated pCS2 variants, termed pCS2 + 8, that facilitate the construction of untagged, as well as N- and C-terminal transporter fusions in a common vector backbone (Fig. 2) (Addgene.org; Gökirmak et al., 2012). The resulting mRNAs are injected into a one-cell embryo, which is then cultured to allow sufficient time for expression. We often assess efflux on early blastulae (12–20 hr post-fertilization) (Fig. 2) since the embryos are still immobile at this stage, and consist of a single layer of polarized cells (Itza and Mozingo, 2005). By this time, more than 90% of the observed efflux activity can come from the recombinant protein, thus providing a system in which to test subtle differences in functions of homologs, paralogs, mutants or splice variants. For example, we found that two amino acids in transmembrane helix (TMH) 6 are responsible for differences in stereoselectivity of sea urchin versus mouse ABCB1a (Gökirmak et al., 2012).

Recombinant protein expression informs also provides information regarding the subcellular localization of a specific transporter. For example, Figure 3 shows recombinant versions of 12 ABC transporters representing B-, C-, and G-subfamilies. Of these, five, –ABCB1a, ABCB4a, ABCC1 β (a splice variant of ABCC1), ABCC5a, and ABCG2a—are plasma membrane transporters with a clear efflux activity for fluorescent substrates (Table 1) (Gökirmak et al., 2012). Conversely, two basolateral transporters, ABCB1b and ABCC4, and an apical transporter, ABCG2c, do not appear to have activity against any of the substrates we have tested to date. Four half transporters –ABCB6, ABCB7, ABCB8, and ABCC9a (SUR2 homolog)— have organellar membrane localizations (Fig. 3), consistent with the residence of their closest mammalian homologs.

Modeling Transporter Location Within the Embryo

Merging physiological studies with developmental “mapping” approaches (quantitative PCR and in situ hybridization) can further refine our membrane localization models in sea urchins (Fig. 4), which implicate spatial and temporal restriction of transporters with specific morphogenetic or protective functions. For example, we found that the predicted xenobiotic transporter ABCB1a is expressed at high levels and is present in most cells of the embryo throughout the first three days of development.




Figure 2. Mapping subcellular location and determining substrate specificity of sea urchin ABC transporters. 1: Full-length coding sequences of ABC transporters are cloned into pCS2 + 8 multicolor plasmids. 2: N- and C-terminal fluorescent protein fusions or untagged variants of each ABC transporter are generated to test the positional effect of the fluorescent protein tag on protein localization and expression. 3: Synthetic ABC transporter mRNA is synthesized in vitro from linearized plasmid, and is then microinjected into fertilized embryos. 4: Subcellular localizations and (5) efflux activities of each tagged ABC transporter are determined in blastulae using confocal microscopy.

In contrast, ABCC5a, which is similar to a human homolog implicated in signaling, is expressed in a spatially and temporally restricted fashion that is consistent with a function in developmental signaling (Shipp and Hamdoun, 2012). Activity and localization assays indicated that ABCB1a is a polyspecific, apical transporter (i.e. facing the environment), whereas ABCC5a is basolateral (facing neighboring cells and the blastocoel) and has minimal xenobiotic efflux activity (Gökirmak et al., 2012; Shipp and Hamdoun, 2012). Together, these recombinant protein and gene expression studies can be used to model plasma membrane protein localization during development (Fig. 4).

Future Approaches to Link Specific Substrates to Developmentally Relevant Transporters

One future direction will be to connect what we are learning about the spatial and temporal distribution of transporters in embryos to an understanding of their substrates. While MDR transporters efflux many signaling molecules important for reproduction and development, few fluorescent analogs of these compounds are available. Vesicular transport studies with overexpressed

proteins are an important alternative approach for studying the translocation of such transporters (Horio et al., 1988). Indeed, several membrane systems—including insect cells (Bakos et al., 1998; Fischer et al., 2013), transfected or selected mammalian cell lines (Zeng et al., 2000), artificial membrane vesicles (Sharom et al., 1999), or monolayer transport assays (Polli et al., 2001)—have previously been used to directly measure the translocation of a radioactively labeled substrate across a cell membrane. Since active transport of substrates across cell membranes by ABC transporters requires hydrolysis of ATP molecules and the release of inorganic phosphate (P_i) and ADP, ATPase assays with purified transporters can also be used to measure the rate of P_i liberation after stimulation with a presumed developmental substrate (Baykov et al., 1988; Henkel et al., 1988). It is generally accepted that compounds that stimulate ATPase activity are substrates, while those that inhibit ATPase activity are inhibitors (Al-Shawi et al., 2003). Additionally, vesicular transport assays have recently been combined with liquid chromatography/mass spectrometry (LC/MS)-based metabolomics to identify physiological MDR transporter substrates (Krum-pochova et al., 2012).




Figure 3. Subcellular localization of mCherry-tagged sea urchin ABC transporters (*Sp-ABC*) in blastulae. ABC-B1a, B4a, G2a, and G2c localize to apical membranes in *S. purpuratus* embryos. ABC-B1b, C1, C4, and C5a localize to basolateral membranes. ABC-B6, B7, B8, and C9a localize into internal/organellar membranes. Scale bar, 20 μm .




Figure 4. Spatio-temporal mapping of transporters. 1: Temporal expression patterns of transporters reveal developmental stages in which transporters are expressed. For example, ABCB1a expression is not restricted to a specific developmental stage, while ABCC5a expression is primarily expressed at and after the mesenchyme blastula stage. 2: Spatial patterns of transporter expression are determined by in situ hybridization. ABCB1a is expressed in all cells of the embryo, while ABCC5a is only expressed in non-skeletogenic mesenchyme cells (blue). 3: Subcellular localization of relevant proteins are determined by the expression of fluorescent protein fusions of a transporter (red) (see also Figs. 2 and 3). For example, ABCB1a localizes to the apical membrane while ABCC5a localizes to basolateral membranes. 4: Data are merged to model endogenous transporter protein expression and function. 5: Models are tested by assessing endogenous protein expression, developmental function, and xenobiotic efflux activity.

CONCLUSIONS

Despite the significance of membrane transport, our understanding of plasma membrane transporters in embryos remains rudimentary. While membrane transport has long been studied in adult cells, such as hepatocytes or in cancer cells, there are several challenges to applying this existing information to embryos. First, unlike membrane transport in differentiated cell models, such as adipocytes, neurons, hepatocytes, or renal cells, the surfaces of embryonic cells are dynamic, and transporter composition changes rapidly with differentiation. Second, the number of transporters is large, and transport is often mediated by the simultaneous action of multiple, overlapping/redundant transporters (Giacomini et al., 2010). Finally, unlike most enzymes, membrane transporters are polyspecific, i.e., have multiple substrates. Thus, MDR transporters can be thought of as being more like Swiss army knives than vegetable peelers, with functions dictated by the cellular context in which they are expressed.

Nonetheless, the challenges underlying the identification of embryonic membrane transporter function are essential to tackle for several reasons. The first is simply that the functions of many membrane transporters are incompletely understood in any system. As illustrated here, understanding how these proteins are regulated in space and time in an embryo can be an important tool for generating hypotheses about their potential functions. This is especially relevant given that the expression of membrane transporters in diseases such as cancer can itself result from recapitulation of developmental pathways, including the epithelial-to-mesenchymal transformation pathways. Further, as alluded to above, the actual function of those transporters in disease can be analogous to their developmental roles, such as controlling cell motility. Thus, coming to grips with the diversity of functions and regulatory pathways that these Swiss army knives participate in may require insight from embryos.

REFERENCES

- Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH. 2002. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. *Mol Cancer Ther* 1:417–425.
- Almén MS, Nordström KJ, Fredriksson R, Schiöth HB. 2009. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. *BMC Biol* 7:50.
- Al-Shawi MK, Polar MK, Omote H, Figler RA. 2003. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. *J Biol Chem* 278:52629–52640.
- Anselmo HM, van den Berg JH, Rietjens IM, Murk AJ. 2012. Inhibition of cellular efflux pumps involved in multi xenobiotic resistance (MXR) in echinoid larvae as a possible mode of action for increased ecotoxicological risk of mixtures. *Ecotoxicology* 21:2276–2287.
- Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. 2009. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. *Cancer Res* 69:5820–5828.
- Babcock JJ, Li M. 2014. Deorphanizing the human transmembrane genome: A landscape of uncharacterized membrane proteins. *Acta Pharmacol Sin* 35:11–23.
- Bakos E, Evers R, Szakács G, Tusnády GE, Welker E, Szabó K, de Haas M, van Deemter L, Borst P, Váradi A, Sarkadi B. 1998. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. *J Biol Chem* 273:32167–32175.
- Baldes C, Koenig P, Neumann D, Lenhof HP, Kohlbacher O, Lehr CM. 2006. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). *Eur J Pharm Biopharm* 62:39–43.
- Barbet R, Peiffer I, Hutchins JR, Hatzfeld A, Garrido E, Hatzfeld JA. 2012. Expression of the 49 human ATP binding cassette (ABC) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: Possible role of ABC plasma membrane transporters in maintaining human stem cell pluripotency. *Cell Cycle* 11:1611–1620.
- Baykov AA, Evtushenko OA, Avaeva SM. 1988. A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. *Anal Biochem* 171:266–270.
- Beumer KJ, Trautman JK, Bozas A, Liu JL, Rutter J, Gall JG, Carroll D. 2008. Efficient gene targeting in *Drosophila* by direct embryo injection with zinc-finger nucleases. *Proc Natl Acad Sci U S A* 105:19821–19826.
- Borst P, Elferink RO. 2002. Mammalian ABC transporters in health and disease. *Annu Rev Biochem* 71:537–592.
- Bosnjak I, Segvic T, Smital T, Franeki J, Mladineo I. 2011. Sea urchin embryotoxicity test for environmental contaminants - potential role of the MRP proteins. *Water Air Soil Pollut* 217:627–636.
- Bosnjak I, Uhlinger KR, Heim W, Smital T, Franeki-Coli J, Coale K, Epel D, Hamdoun A. 2009. Multidrug efflux transporters limit accumulation of inorganic, but not organic, mercury in sea urchin embryos. *Environ Sci Technol* 43:8374–8380.
- Campanale JP, Hamdoun A. 2012. Programmed reduction of ABC transporter activity in sea urchin germline progenitors. *Development* 139:783–792.
- Campanale JP, Gökirmak T, Espinoza JA, Oulhen N, Wessel GM, Hamdoun A. 2014. Migration of sea urchin primordial germ cells. *Dev Dyn* 243:917–927.
- Cheepala S, Hulot JS, Morgan JA, Sassi Y, Zhang W, Naren AP, Schuetz JD. 2013. Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. *Annu Rev Pharmacol Toxicol* 53:231–253.
- Cheers MS, Etensohn CA. 2004. Rapid microinjection of fertilized eggs. *Methods Cell Biol* 74:287–310.
- Churamani D, Geach TJ, Ramakrishnan L, Prideaux N, Patel S, Dale L. 2012. The signaling protein CD38 is essential for early embryonic development. *J Biol Chem* 287:6974–6978.
- Cole BJ, Hamdoun A, Epel D. 2013. Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos. *J Exp Biol* 216:3896–3905.
- Cole SP. 2014. Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. *Annu Rev Pharmacol Toxicol* 54:95–117.
- Crivellato E, Candussio L, Rosati AM, Bartoli-Klugmann F, Mallardi F, Decorti G. 2002. The fluorescent probe Bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance-related protein (MRP)-1. *J Histochem Cytochem* 50:731–734.
- Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L, Paul DC, Williams DC, Peng SB, Slapak CA, Godinot N, Perry WL. 2004. Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters. *Biochem Pharmacol* 67:1111–1121.
- de Bruin M, Miyake K, Litman T, Robey R, Bates SE. 1999. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett* 146:117–126.
- De Souza MQ, Barros TV, Torrezan E, Cavalcanti AL, Figueiredo RC, Marques-Santos LF. 2010. Characterization of functional activity of ABCB1 and ABCC1 proteins in eggs and embryonic cells of the sea urchin *Echinometra lucunter*. *Biosci Rep* 30:257–265.
- Dean M, Hamon Y, Chimini G. 2001. The human ATP-binding cassette (ABC) transporter superfamily. *J Lipid Res* 42:1007–1017.

- Deeley RG, Cole SP. 2006. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). *FEBS Lett* 580: 1103–1111.
- Draper MP, Martell RL, Levy SB. 1997. Active efflux of the free acid form of the fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. *Eur J Biochem* 243: 219–224.
- Epel D, Cole B, Hamdoun A, Thurber RV. 2006. The sea urchin embryo as a model for studying efflux transporters: Roles and energy cost. *Mar Environ Res* 62:S1–4.
- Epel D, Luckenbach T, Stevenson CN, Macmanus-Spencer LA, Hamdoun A, Smital T. 2008. Efflux transporters: newly appreciated roles in protection against pollutants. *Environ Sci Technol* 42:3914–3920.
- Erdei Z, Lrincz R, Szabéni K, Péntek A, Varga N, Likó I, Várady G, Szakács G, Orbán TI, Sarkadi B, Apáti A. 2014. Expression pattern of the human ABC transporters in pluripotent embryonic stem cells and in their derivatives. *Cytometry B Clin Cytom* [Epub ahead of print].
- Essodaigui M, Broxterman HJ, Garnier-Suillerot A. 1998. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. *Biochemistry* 37:2243–2250.
- Fischer S, Klüver N, Burkhardt-Medicke K, Pietsch M, Schmidt AM, Wellner P, Schirmer K, Luckenbach T. 2013. Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (*Danio rerio*) embryos. *BMC Biol* 11:69.
- Fletcher JI, Haber M, Henderson MJ, Norris MD. 2010. ABC transporters in cancer: More than just drug efflux pumps. *Nat Rev Cancer* 10:147–156.
- Ford JM, Hait WN. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. *Pharmacol Rev* 42:155–199.
- Fu D, Wakabayashi Y, Lippincott-Schwartz J, Arias IM. 2011. Bile acid stimulates hepatocyte polarization through a cAMP-Epac-MEK-LKB1-AMPK pathway. *Proc Natl Acad Sci U S A* 108:1403–1408.
- Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW. 1997. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. *Anticancer Drugs* 8:141–155.
- Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Consortium IT. 2010. Membrane transporters in drug development. *Nat Rev Drug Discov* 9: 215–236.
- Goldstone JV, Hamdoun A, Cole BJ, Howard-Ashby M, Nebert DW, Scally M, Dean M, Epel D, Hahn ME, Stegeman JJ. 2006. The chemical defense: Environmental sensing and response genes in the *Strongylocentrotus purpuratus* genome. *Dev Biol* 300:366–384.
- Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. *Nat Rev Cancer* 2:48–58.
- Gökirmak T, Campanale JP, Shipp LE, Moy GW, Tao H, Hamdoun A. 2012. Localization and substrate selectivity of sea urchin multidrug (MDR) efflux transporters. *J Biol Chem* 287: 43876–43883.
- Good JR, Kuspa A. 2000. Evidence that a cell-type-specific efflux pump regulates cell differentiation in *Dictyostelium*. *Dev Biol* 220:53–61.
- Gutmann DA, Ward A, Urbatsch IL, Chang G, van Veen HW. 2010. Understanding polyspecificity of multidrug ABC transporters: Closing in on the gaps in ABCB1. *Trends Biochem Sci* 35:36–42.
- Haimeur A, Conseil G, Deeley RG, Cole SP. 2004. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. *Curr Drug Metab* 5:21–53.
- Hamdoun AM, Cherr GN, Roepke TA, Epel D. 2004. Activation of multidrug efflux transporter activity at fertilization in sea urchin embryos (*Strongylocentrotus purpuratus*). *Dev Biol* 276: 452–462.
- Hamdoun AM, Griffin FJ, Cherr GN. 2002. Tolerance to biodegraded crude oil in marine invertebrate embryos and larvae is associated with expression of a multixenobiotic resistance transporter. *Aquat Toxicol* 61:127–140.
- Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL. 2001. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. *J Pharmacol Exp Ther* 298: 1199–1205.
- Henkel RD, VandeBerg JL, Walsh RA. 1988. A microassay for ATPase. *Anal Biochem* 169:312–318.
- Holland LZ, Yu JK. 2004. Cephalochordate (amphioxus) embryos: Procurement, culture, and basic methods. *Methods Cell Biol* 74:195–215.
- Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. 1993. Fluorescent cellular indicators are extruded by the multidrug resistance protein. *J Biol Chem* 268:21493–21496.
- Homolya L, Holló M, Müller M, Mechetner EB, Sarkadi B. 1996. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. *Br J Cancer* 73: 849–855.
- Homolya L, Fu D, Sengupta P, Jarnik M, Gillet JP, Vitale-Cross L, Gutkind JS, Lippincott-Schwartz J, Arias IM. 2014. LKB1/AMPK and PKA control ABCB11 trafficking and polarization in hepatocytes. *PLoS One* 9:e91921.

- Horio M, Gottesman MM, Pastan I. 1988. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. *Proc Natl Acad Sci USA* 85:3580–3584.
- Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. *Cancer Res* 53:4595–4602.
- Itza EM, Mozingo NM. 2005. Septate junctions mediate the barrier to paracellular permeability in sea urchin embryos. *Zygote* 13:255–264.
- Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD. 2011. The “specific” P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). *ACS Chem Neurosci* 2:82–89.
- Kazazoglou T, Schackmann RW, Fosset M, Shapiro BM. 1985. Calcium channel antagonists inhibit the acrosome reaction and bind to plasma membranes of sea urchin sperm. *Proc Natl Acad Sci U S A* 82:1460–1464.
- Keppler D. 2011. Multidrug resistance proteins (MRPs, ABCs): Importance for pathophysiology and drug therapy. *Handb Exp Pharmacol* 299–323.
- Keppler D, Cui Y, König J, Leier I, Nies A. 1999. Export pumps for anionic conjugates encoded by MRP genes. *Adv Enzyme Regul* 39:237–246.
- Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. 2002. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. *Mol Pharmacol* 62:1–6.
- Korolnek T, Zhang J, Beardsley S, Scheffer GL, Hamza I. 2014. Control of metazoan heme homeostasis by a conserved multidrug resistance protein. *Cell Metab* 19:1008–1019.
- Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci* 11:265–283.
- Krumpochova P, Saptho S, Brouwers JF, de Haas M, de Vos R, Borst P, van de Wetering K. 2012. Transportomics: Screening for substrates of ABC transporters in body fluids using vesicular transport assays. *FASEB J* 26:738–747.
- Layden MJ, Röttinger E, Wolenski FS, Gilmore TD, Martindale MQ. 2013. Microinjection of mRNA or morpholinos for reverse genetic analysis in the starlet sea anemone, *Nematostella vectensis*. *Nat Protoc* 8:924–934.
- Lebedeva IV, Pande P, Patton WF. 2011. Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. *PLoS One* 6:e22429.
- Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. 1994. The MRP gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates. *J Biol Chem* 269:27807–27810.
- Leite JC, de Vasconcelos RB, da Silva SG, de Siqueira-Junior JP, Marques-Santos LF. 2014. ATP-binding cassette transporters protect sea urchin gametes and embryonic cells against the harmful effects of ultraviolet light. *Mol Reprod Dev* 81:66–83.
- Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM, Willingham MC. 1991. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. *Mol Pharmacol* 40:490–494.
- Limtrakul P, Chearwae W, Shukla S, Phisalpong C, Ambudkar SV. 2007. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. *Mol Cell Biochem* 296:85–95.
- Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. 2000. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). *J Cell Sci* 113:2011–2021.
- Long Y, Li Q, Li J, Cui Z. 2011. Molecular analysis, developmental function and heavy metal-induced expression of ABCC5 in zebrafish. *Comp Biochem Physiol B Biochem Mol Biol* 158:46–55.
- Londesborough A, Vaahtomeri K, Tiainen M, Katajisto P, Ekman N, Vallenius T, Mäkelä TP. 2008. LKB1 in endothelial cells is required for angiogenesis and TGFβ-mediated vascular smooth muscle cell recruitment. *Development* 135:2331–2338.
- Maeno K, Nakajima A, Conseil G, Rothnie A, Deeley RG, Cole SP. 2009. Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). *Drug Metab Dispos* 37:1411–1420.
- Marques-Santos LF, Oliveira JG, Maia RC, Rumjanek VM. 2003. Mitotracker green is a P-glycoprotein substrate. *Biosci Rep* 23:199–212.
- Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. 1999. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. *Br J Pharmacol* 128:403–411.
- Matsson P, Englund G, Ahlin G, Bergström CA, Norinder U, Artursson P. 2007. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). *J Pharmacol Exp Ther* 323:19–30.
- Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. *Pharm Res* 26:1816–1831.
- McAleer MA, Breen MA, White NL, Matthews N. 1999. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. *J Biol Chem* 274:23541–23548.

- Meyer E, Manahan DT. 2009. Nutrient uptake by marine invertebrates: Cloning and functional analysis of amino acid transporter genes in developing sea urchins (*Strongylocentrotus purpuratus*). *Biol Bull* 217:6–24.
- Miranda ER, Zhuchenko O, Toplak M, Santhanam B, Zupan B, Kuspa A, Shaluský G. 2013. ABC transporters in *Dictyostelium discoideum* development. *PLoS One* 8:e70040.
- Norman BH, Lander PA, Gruber JM, Kroin JS, Cohen JD, Jungheim LN, Starling JJ, Law KL, Self TD, Tabas LB, Williams DC, Paul DC, Dantzig AH. 2005. Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). *Bioorg Med Chem Lett* 15: 5526–5530.
- Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. 2009. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. *Invest New Drugs* 27:31–40.
- Perrotton T, Tromprier D, Chang XB, Di Pietro A, Baubichon-Cortay H. 2007. (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. *J Biol Chem* 282:31542–31548.
- Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL. 1992. A phase I study on the reversal of multidrug resistance (MDR) in vivo: Nifedipine plus etoposide. *Br J Cancer* 65:267–270.
- Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. *J Pharmacol Exp Ther* 299: 620–628.
- Postel R, Ketema M, Kuikman I, de Pereda JM, Sonnenberg A. 2011. Nesprin-3 augments peripheral nuclear localization of intermediate filaments in zebrafish. *J Cell Sci* 124:755–764.
- Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. 2005. Cyclosporin A is a broad-spectrum multidrug resistance modulator. *Clin Cancer Res* 11:2320–2326.
- Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. 2000. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. *Cancer Res* 60:47–50.
- Raggers RJ, Vogels I, van Meer G. 2001. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. *Biochem J* 357:859–865.
- Ricardo S, Lehmann R. 2009. An ABC transporter controls export of a *Drosophila* germ cell attractant. *Science* 323:943–946.
- Robert J, Jarry C. 2003. Multidrug resistance reversal agents. *J Med Chem* 46:4805–4817.
- Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE. 2004. Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res* 64:1242–1246.
- Roepke TA, Hamdoun AM, Cherr GN. 2006. Increase in multidrug transport activity is associated with oocyte maturation in sea stars. *Dev Growth Differ* 48:559–573.
- Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T, Yokota J. 2010. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. *Lung Cancer* 70:136–145.
- Russel FG, Koenderink JB, Masereeuw R. 2008. Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. *Trends Pharmacol Sci* 29:200–207.
- Sai Y, Tsuji A. 2004. Transporter-mediated drug delivery: Recent progress and experimental approaches. *Drug Discov Today* 9:712–720.
- Saxena M, Stephens MA, Pathak H, Rangarajan A. 2011. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. *Cell Death Dis* 2:e179.
- Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. *Pharmacogenomics* 9:105–127.
- Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabó K, Müller M, Hose CD, Monks A, Váradi A, Seprödi J, Sarkadi B. 1999. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. *Biochem Pharmacol* 58:571–586.
- Shipp LE, Hamdoun A. 2012. ATP-binding cassette (ABC) transporter expression and localization in sea urchin development. *Dev Dyn* 241:1111–1124.
- Smital T, Luckenbach T, Sauerborn R, Hamdoun AM, Vega RL, Epel D. 2004. Emerging contaminants—pesticides, PPCPs, microbial degradation products and natural substances as inhibitors of multixenobiotic defense in aquatic organisms. *Mutat Res* 552:101–117.
- Sodergren E, Weinstock GM, Davidson EH, Cameron RA, Gibbs RA, Angerer RC, Angerer LM, Arnone MI, Burgess DR, Burke RD, Coffman JA, Dean M, Elphick MR, Etensohn CA, Foltz KR, Hamdoun A, Hynes RO, Klein WH, Marzluff W, McClay DR, Morris RL, Mushegian A, Rast JP, Smith LC, Thorndyke MC, Vacquier VD, Wessel GM, Wray G, Zhang L, Elsik CG, Ermolaeva O, Hlavina W, Hofmann G, Kitts P, Landrum MJ, Mackey AJ, Maglott D, Panopoulou G, Poustka AJ, Pruitt K, Sapojnikov V, Song X, Souvorov A, Solovyev V, Wei Z, Whittaker CA, Worley K, Durbin KJ, Shen Y, Fedrigo O, Garfield D, Haygood R, Primus A, Satija R, Severson T, Gonzalez-Garay ML, Jackson AR, Milosavljevic A, Tong M, Killian CE, Livingston BT, Wilt FH, Adams N, Bellé R, Carbonneau S, Cheung R, Cormier P, Cosson B, Croce J, Fernandez-Guerra A, Genevière AM, Goel M, Kelkar H, Morales J, Mulner-Lorillon O, Robertson AJ, Goldstone JV, Cole B, Epel D, Gold B, Hahn ME, Howard-Ashby M, Scally M, Stegeman JJ, Allgood EL, Cool J, Judkins KM, McCafferty SS, Musante AM, Obar RA, Rawson AP, Rossetti BJ, Gibbons

- IR, Hoffman MP, Leone A, Istrail S, Materna SC, Samanta MP, Stolc V, Tongprasit W, Tu Q, Bergeron KF, Brandhorst BP, Whittle J, Berney K, Bottjer DJ, Calestani C, Peterson K, Chow E, Yuan QA, Elhaik E, Graur D, Reese JT, Bosdet I, Heesun S, Marra MA, Schein J, Anderson MK, Brockton V, Buckley KM, Cohen AH, Fugmann SD, Hibino T, Loza-Coll M, Majeske AJ, Messier C, Nair SV, Pancer Z, Terwilliger DP, Agca C, Arboleda E, Chen N, Churcher AM, Hallböök F, Humphrey GW, Idris MM, Kiyama T, Liang S, Mellott D, Mu X, Murray G, Olinski RP, Raible F, Rowe M, Taylor JS, Tessmar-Raible K, Wang D, Wilson KH, Yaguchi S, Gaasterland T, Galindo BE, Gunaratne HJ, Juliano C, Kinukawa M, Moy GW, Neill AT, Nomura M, Raisch M, Reade A, Roux MM, Song JL, Su YH, Townley IK, Voronina E, Wong JL, Amore G, Branno M, Brown ER, Cavalieri V, Duboc V, Duloquin L, Flytzanis C, Gache C, Lapraz F, Lepage T, Locascio A, Martinez P, Matassi G, Matranga V, Range R, Rizzo F, Röttinger E, Beane W, Bradham C, Byrum C, Glenn T, Hussain S, Manning G, Miranda E, Thomason R, Walton K, Wikramanayake A, Wu SY, Xu R, Brown CT, Chen L, Gray RF, Lee PY, Nam J, Oliveri P, Smith J, Muzny D, Bell S, Chacko J, Cree A, Curry S, Davis C, Dinh H, Dugan-Rocha S, Fowler J, Gill R, Hamilton C, Hernandez J, Hines S, Hume J, Jackson L, Jolivet A, Kovar C, Lee S, Lewis L, Miner G, Morgan M, Nazareth LV, Okwuonu G, Parker D, Pu LL, Thorn R, Wright R. Consortium SUGS. 2006. The genome of the sea urchin *Strongylocentrotus purpuratus*. *Science* 314: 941–952.
- Solek CM, Oliveri P, Loza-Coll M, Schrankel CS, Ho EC, Wang G, Rast JP. 2013. An ancient role for Gata-1/2/3 and Scl transcription factor homologs in the development of immunocytes. *Dev Biol* 382:280–292.
- Sprachman MM, Laughney AM, Kohler RH, Weissleder R. 2014. In vivo imaging of multidrug resistance using a third generation MDR1 inhibitor. *Bioconjug Chem* 25:1137–1142
- Strouse JJ, Ivnitski-Steele I, Waller A, Young SM, Perez D, Evangelisti AM, Ursu O, Bologa CG, Carter MB, Salas VM, Tegos G, Larson RS, Oprea TI, Edwards BS, Sklar LA. 2013. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters. *Anal Biochem* 437: 77–87.
- Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. 2006. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 5:219–234.
- Szakács G, Váradi A, Ozvegy-Laczkó C, Sarkadi B. 2008. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). *Drug Discov Today* 13:379–393.
- Tegos GP, Evangelisti AM, Strouse JJ, Ursu O, Bologa C, Sklar LA. 2014. A high throughput flow cytometric assay platform targeting transporter inhibition. *Drug Discov Today* 12: e95–e103
- Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. *Cell* 139:871–890.
- Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* 41:1967–1972.
- Twentyman PR. 1992. Cyclosporins as drug resistance modifiers. *Biochem Pharmacol* 43:109–117.
- Vasiliou V, Vasiliou K, Nebert DW. 2009. Human ATP-binding cassette (ABC) transporter family. *Hum Genomics* 3:281–290.
- Wakabayashi Y, Kipp H, Arias IM. 2006. Transporters on demand: Intracellular reservoirs and cycling of bile canalicular ABC transporters. *J Biol Chem* 281:27669–27673.
- Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. 2007. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. *Drug Metab Dispos* 35: 340–344.
- Whalen K, Reitzel AM, Hamdoun A. 2012. Actin polymerization controls the activation of multidrug efflux at fertilization by translocation and fine-scale positioning of ABCB1 on microvilli. *Mol Biol Cell* 23:3663–3672.
- Wu CP, Ohnuma S, Ambudkar SV. 2011a. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. *Curr Pharm Biotechnol* 12:609–620.
- Wu W, Dnyanmote AV, Nigam SK. 2011b. Remote communication through solute carriers and ATP binding cassette drug transporter pathways: An update on the remote sensing and signaling hypothesis. *Mol Pharmacol* 79:795–805.
- Xu X, Fu J, Wang H, Zhang B, Wang X, Wang Y. 2011. Influence of P-glycoprotein on embryotoxicity of the antifouling biocides to sea urchin (*Strongylocentrotus intermedius*). *Ecotoxicology* 20:419–428.
- Yabe T, Suzuki N, Furukawa T, Ishihara T, Katsura I. 2005. Multidrug resistance-associated protein MRP-1 regulates dauer diapause by its export activity in *Caenorhabditis elegans*. *Development* 132:3197–3207.
- Yang J, Weinberg RA. 2008. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. *Dev Cell* 14:818–829.
- Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M, Mäkelä TP. 2001. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science* 293: 1323–1326.
- Young RN. 1991. Development of novel leukotriene-based anti-asthma drugs: MK-886 and MK-571. *Agents Actions Suppl* 34:179–187.
- Yusa K, Tsuruo T. 1989. Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. *Cancer Res* 49: 5002–5006.

Zeng H, Liu G, Rea PA, Kruh GD. 2000. Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res* 60:4779–4784.

Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Annable T, Arceci RJ, Durr FE, Greenberger LM. 1994.

P-glycoprotein mediates profound resistance to bisantrene. *Oncol Res* 6:291–301.

Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q. 2005. BCRP transports dipyridamole and is inhibited by calcium channel blockers. *Pharm Res* 22:2023–2034.

MRD